People: Senomyx Inc (SNMX.OQ)

SNMX.OQ on NASDAQ Stock Exchange Global Market

2.77USD
1 Aug 2013
Price Change (% chg)

$0.13 (+4.92%)
Prev Close
$2.64
Open
$2.64
Day's High
$2.83
Day's Low
$2.60
Volume
51,556
Avg. Vol
17,879
52-wk High
$3.02
52-wk Low
$1.53

Search Stocks

Summary

Name Age Since Current Position

Kent Snyder

58 2009 Chairman of the Board, Chief Executive Officer

John Poyhonen

52 2009 President, Chief Operating Officer

Antony Rogers

45 2012 Chief Financial Officer, Senior Vice President

Donald Karanewsky

60 2010 Senior Vice President, Chief Scientific Officer

David Berger

2012 Senior Vice President, General Counsel, Corporate Secretary

Sharon Wicker

56 2009 Senior Vice President and Chief Commercial Development Officer

Jay Short

2008 Lead Independent Director

Roger Billingsley

60 2008 Independent Director

Stephen Block

67 2005 Independent Director

Mary Gray

60 2010 Independent Director

Michael Herman

70 2005 Independent Director

Christopher Twomey

52 2006 Independent Director

Gwen Rosenberg

Vice President - Investor Relations & Corporate Communications

Biographies

Name Description

Kent Snyder

Mr. Kent Snyder is Chairman of the Board, Chief Executive Officer of Senomyx Inc. He joined Senomyx in June 2003 and has served as Chief Executive Officer and as a member of the Board of Directors since that time. From June 2003 until September 2009 Mr. Snyder also served as President, and since May 2008 Mr. Snyder has served as Chairman of the Board of Directors. From July 1991 to October 2001, Mr. Snyder held various marketing and sales management positions with Agouron Pharmaceuticals, Inc., a Pfizer company. Mr. Snyder’s most recent position was President of Global Commercial Operations, and prior to that Mr. Snyder served as Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder is a director of Santarus, Inc., a publicly-held biopharmaceutical company. Mr. Snyder received his B.S. from the University of Kansas and his M.B.A. from Rockhurst College.

John Poyhonen

Mr. John W. Poyhonen is President, Chief Operating Officer of Senomyx, Inc. He joined the company in October 2003 as Vice President and Chief Business Officer and was promoted in April 2004 to Vice President, Chief Financial and Business Officer. In January 2006, he was promoted to Senior Vice President, Chief Financial and Business Officer and in September 2009 he was promoted to President and Chief Operating Officer. Before joining Senomyx, from 1996 until October 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, a Pfizer company, most recently as Vice President of National Sales. Mr. Poyhonen is a director of Ardea Biosciences, Inc., a biopharmaceutical company. Mr. Poyhonen received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas.

Antony Rogers

Mr. Antony E. Rogers serves as Chief Financial Officer, Senior Vice President of Senomyx Inc., since January 27, 2012. Since joining Senomyx he has served in various roles of increasing responsibility and was appointed Vice President, Finance and Treasury in February 2006, Chief Financial Officer in September 2009 and he was promoted to his current position in January 2012. His previous experience includes various finance and accounting positions with Indiqu, Inc., Ancile Pharmaceuticals, Aurora Biosciences, and Sequana Therapeutics. Mr. Rogers received his B.S. in Accounting from San Diego State University.

Donald Karanewsky

Dr. Donald S. Karanewsky, Ph.D., serves as Senior Vice President, Chief Scientific Officer of Senomyx Inc. From October 2002 to June 2007 Dr. Karanewsky was Executive Director of Chemistry at The Genomics Institute of the Novartis Research Foundation (GNF). At GNF, Dr. Karanewsky had management responsibility for the Departments of Medicinal Chemistry, Analytical Chemistry, Bioanalytical Chemistry, and Compound Management, and was a member of the GNF Drug Discovery Steering Committee and the Novartis Global Discovery Chemistry Leadership Team. Dr. Karanewsky has also directed chemistry research teams and had senior management roles at Ligand Pharmaceuticals and Idun Pharmaceuticals and he previously held principal positions at Glaxo Inc, Bristol-Myers Squibb, and the Squibb Institute for Medical Research. He received his Ph.D. in Chemistry from Harvard University and was granted a B.S. in Chemistry, Magna Cum Laude, from Stevens Institute of Technology in New Jersey. Dr. Karanewsky is an inventor on more than 85 issued US patents and has authored over 70 scientific publications.

David Berger

Mr. David B. Berger, Esq., is no longer Senior Vice President, General Counsel, Corporate Secretary of Senomyx Inc., effective August 2, 2013. Prior to his service at Senomyx, from 2003 until 2007 Mr. Berger was responsible for all commercial aspects of legal affairs at Biosite Incorporated, a publicly traded medical diagnostics company. At Biosite, Mr. Berger most recently held the position of Vice President, Legal Affairs. Previously, Mr. Berger was an attorney at Cooley Godward LLP and Amylin Pharmaceuticals, Inc. Mr. Berger earned his J.D. from Stanford Law School and received his B.A. in Economics at the University of California, Berkeley.

Sharon Wicker

Ms. Sharon Wicker is Senior Vice President and Chief Commercial Development Officer of Senomyx Inc. From when Ms. Wicker joined Senomyx in April 2006 until September 2009 she served as Senior Vice President of Commercial Development and Chief Strategy Officer. From 2003 to 2006, Ms. Wicker held various strategic marketing positions, most recently as President, Flavor Business Unit, at A.M. Todd Company. Prior to 2003 Ms. Wicker held various general management positions with Heinz, ConAgra and General Mills. Ms. Wicker received her B.S. in Food Science and Nutrition from Colorado State University and her M.B.A. from Michigan State University.

Jay Short

Dr. Jay M. Short, Ph.D., serves as Lead Independent Director of Senomyx Inc. Since March 2007, Dr. Short has been Chairman, Chief Executive Officer and Principal of BioAtla, a private protein therapeutics research and development services organization based in San Diego and Beijing. In addition, since August 2011 he has served as Chief Executive Officer for Ciris Energy, a private bioenergy company focused on biogenic gas generation from coal. Dr. Short also is Founder of the E.O. Wilson Biodiversity Foundation, a 501(c)(3) public charity, and served as its President and Chairman from its inception in October 2005 through July 2008. From February 1999 to October 2005, Dr. Short was the President and Chief Executive Officer of Diversa Corporation (now a part of British Petroleum and Verenium). He was also a founder of Diversa Corporation, and served as Chief Technology Officer and as a director of the company from its inception in 1994 until October 2005. Dr. Short is a director and advisor of several privately-held companies, including Ciris Energy, Femta Pharmaceuticals and Taxon Biosciences, and served as a director of Invitrogen Corporation (now Life Technologies Corporation) from 1995 until 2008. In 2006, Dr. Short was shortlisted by the editors of Nature Biotechnology as a personality making the most contribution to biotech in the past decade. Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana. Dr. Short has also attended and received Director Certification from the UCLA Anderson School of Business.

Roger Billingsley

Dr. Roger D. Billingsley, Ph.D., serves as Independent Director of Senomyx Inc., since April 2008. Since March 2008 Dr. Billingsley has been serving as Senior Vice President, Technology and Product Development of Dole Fresh Vegetables, a division of Dole Food Company. From June 2006 to March 2008, he served as Division Vice President of Research and Development and Scientific Affairs of Abbott Nutrition, a division of Abbott Laboratories, Inc. From September 2004 to June 2006, Dr. Billingsley served as Division Vice President of Research and Development and Scientific Affairs of Ross Products, also a division of Abbott Laboratories, Inc. Prior to 2004, Dr. Billingsley held senior management positions at ConAgra Foods, Pet Incorporated, Nabisco Brands, Inc. and Kellogg Company. Dr. Billingsley currently serves as a director of Orange County Business Bank. Dr. Billingsley holds a B.S. and an M.S. from Southern Illinois University, Carbondale, a Ph.D. from the University of Tennessee, Knoxville and a post-doctoral degree from the University of Illinois, Champaign.

Stephen Block

Mr. Stephen A. Block, Esq., serves as Independent Director of Senomyx Inc., since March 2005. Mr. Block served as Chief Legal Officer and Secretary of International Flavors and Fragrances Inc., a creator, manufacturer and seller of flavors and fragrances (IFF), from January 1993 until his retirement in December 2003. He was named Senior Vice President, General Counsel and Secretary of IFF in February 2000. During his eleven years at IFF he also led the company’s Regulatory Affairs department. Prior to 1993, Mr. Block held various management positions, including Senior Vice President, General Counsel and Secretary, with GAF Corporation, a company specializing in specialty chemicals and building materials, and Celanese Corporation, a company specializing in synthetic fibers, chemicals and plastics. Mr. Block currently serves as an industry consultant and as a member of the Executive Committee, Orange County Network, of the Tech Coast Angels, a angel investing group. Mr. Block is also a director of ChromaDex Corporation, a reference standards and ingredient supply company, and of several privately held companies. Mr. Block received his B.A. cum laude in Russian Studies from Yale University and his law degree from the Harvard Law School.

Mary Gray

Dr. Mary Ann Gray, Ph.D., is Independent Director of Senomyx, Inc., since September 27, 2010. Since 2003 Dr. Gray has served as President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray currently serves on the Boards of Directors of two other publicly traded biopharmaceutical companies, Dyax Corp. and Acadia Pharmaceuticals, Inc. At Dyax she is also the lead independent director. Dr. Gray holds a Ph.D. in pharmacology from the University of Vermont and a B.S. in biology from University of South Carolina.

Michael Herman

Mr. Michael E. Herman serves as Independent Director of Senomyx Inc., since May 2005. Since 2006 Mr. Herman has been serving as President of the Herman Trading Company. From January 1992 to December 2000, Mr. Herman was President of the Kansas City Royals Baseball Club. From January 1990 to December 1999, he was Chairman of the Finance and Investment Committee of the Kauffman Foundation and was its President from January 1985 to December 1990. From October 1974 to December 1990, Mr. Herman was the Executive Vice President and Chief Financial Officer of Marion Laboratories. Mr. Herman is a director of Santarus, Inc., a biopharmaceutical company, Cerner Corporation, a health care information technology company, and also is a Trustee of Rensselaer Polytechnic Institute and the University of Chicago Graduate School of Business. Mr. Herman holds a B.S. in metallurgical engineering from Rensselaer Polytechnic Institute and an M.B.A. from the University of Chicago.

Christopher Twomey

Mr. Christopher J. Twomey serves as Independent Director of Senomyx Inc., since March 2006. Mr. Twomey joined Biosite Incorporated, a medical diagnostics company, in March 1990 serving in various roles of increasing responsibility, and most recently serving as Senior Vice President, Finance and Chief Financial Officer until his retirement in 2007. At Biosite he was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an audit manager. Mr. Twomey is a director of Cadence Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Twomey holds a B.A. from the University of California at Santa Barbara.

Gwen Rosenberg

Basic Compensation

Name Fiscal Year Total

Kent Snyder

2,406,000

John Poyhonen

1,307,860

Antony Rogers

900,531

Donald Karanewsky

969,222

David Berger

936,864

Sharon Wicker

655,955

Jay Short

--

Roger Billingsley

--

Stephen Block

--

Mary Gray

--

Michael Herman

--

Christopher Twomey

--

Gwen Rosenberg

--
As Of 30 Dec 2011

Options Compensation

Search Stocks